Testosterone cipionate
- PDF / 169,714 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 91 Downloads / 155 Views
1 S
Prostatic metaplasia of vagina and exocervix: 7 case reports In a study involving 13 patients, seven female to male transgender patients aged 18–34 years were described, who developed prostatic metaplasia of vagina or exocervix while receiving testosterone cipionate for gender dysphoria [routes, dosages, times to reactions onsets and outcomes not stated]. The patients were natal females. Six of the seven patients received masculinizing androgen therapy with testosterone cipionate [testosterone cypionate] for gender dysphoria for 24–72 months. The remaining one patient received masculinizing androgen therapy with testosterone cipionate for gender dysphoria. Six of the seven patients had previously undergone hysterectomy as well as bilateral salpingo-oophorectomy as part of the transition. The patients underwent vaginectomy (6 patients) and hysterectomy (1 patient) as gender-affirming surgery. Histologic examination of vaginectomy or hysterectomy specimen showed the following: transitional metaplasia at vagina or exocervix, gland distribution: surface epithelium and one to six blocks were involved. Immunohistochemistry showed the following: NKX3.1, androgen receptor and CK7 were positive and prostate specific antigen was positive or negative. All the microscopic findings were consistent with prostatic metaplasia of vagina (6 patients) and vagina as well as exocervix (1 patient), which were attributed to testosterone cipionate. Anderson WJ, et al. Prostatic Metaplasia of the Vagina and Uterine Cervix: An Androgen-associated Glandular Lesion of Surface Squamous Epithelium. American Journal of 803515105 Surgical Pathology 44: 1040-1049, No. 8, Aug 2020. Available from: URL: http://doi.org/10.1097/PAS.0000000000001486
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
